These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. Wilson K; Bowen D; Francis P; Tyrrell P Br J Psychiatry; 1991 Apr; 158():558-62. PubMed ID: 2054572 [TBL] [Abstract][Full Text] [Related]
5. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Tune L; Brandt J; Frost JJ; Harris G; Mayberg H; Steele C; Burns A; Sapp J; Folstein MF; Wagner HN Acta Psychiatr Scand Suppl; 1991; 366():61-5. PubMed ID: 1897377 [TBL] [Abstract][Full Text] [Related]
6. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial. Jenike MA; Albert MS; Heller H; Gunther J; Goff D J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997 [TBL] [Abstract][Full Text] [Related]
7. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease. Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043 [TBL] [Abstract][Full Text] [Related]
8. L-deprenyl and physostigmine for the treatment of Alzheimer's disease. Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774 [TBL] [Abstract][Full Text] [Related]
9. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. van Dyck CH; Newhouse P; Falk WE; Mattes JA Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618 [TBL] [Abstract][Full Text] [Related]
10. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716 [TBL] [Abstract][Full Text] [Related]